Slezak Jonathan M, Mueller Melanie, Ricaurte George A, Katz Jonathan L
Department of Psychology, Mount St. Mary's University, Emmitsburg.
Department of Neurology, School of Medicine, Johns Hopkins University.
Behav Pharmacol. 2018 Sep;29(6):551-556. doi: 10.1097/FBP.0000000000000409.
Amphetamine is a common therapeutic agent for alleviating the core symptoms associated with attention-deficit hyperactivity disorder (ADHD) in children and adults. The current study used a translational model of attention, the five-choice serial reaction time (5-CSRT) procedure with rats, to examine the time-course effects of d-amphetamine. Effects of different dosages of d-amphetamine were related to drug-plasma concentrations, fashioned after comprehensive pharmacokinetic/pharmacodynamic assessments that have been employed in clinical investigations. We sought to determine whether acute drug-plasma concentrations that enhance performance in the 5-CSRT procedure are similar to those found to be therapeutic in patients diagnosed with ADHD. Results from the pharmacokinetic/pharmacodynamic assessment indicate that d-amphetamine plasma concentrations associated with improved performance on the 5-CSRT procedure overlap with those that have been reported to be therapeutic in clinical trials. The current findings suggest that the 5-CSRT procedure may be a useful preclinical model for predicting the utility of novel ADHD therapeutics and their effective concentrations.
苯丙胺是一种常用的治疗药物,用于缓解儿童和成人注意力缺陷多动障碍(ADHD)的核心症状。当前的研究采用了一种注意力的转化模型,即大鼠的五选择连续反应时(5-CSRT)程序,来研究右旋苯丙胺的时效作用。不同剂量右旋苯丙胺的作用与药物血浆浓度相关,这是根据临床研究中采用的全面药代动力学/药效学评估得出的。我们试图确定在5-CSRT程序中提高表现的急性药物血浆浓度是否与在被诊断为ADHD的患者中发现具有治疗作用的浓度相似。药代动力学/药效学评估的结果表明,与5-CSRT程序中表现改善相关的右旋苯丙胺血浆浓度与临床试验中报道具有治疗作用的浓度重叠。当前的研究结果表明,5-CSRT程序可能是一种有用的临床前模型,用于预测新型ADHD治疗药物的效用及其有效浓度。